Thienopyridine sulfonamide pyrrolidinones were found to be potent and selective inhibitors of the coagulation cascade enzyme factor Xa. SAR studies led to several compounds that were selected for further in vivo investigation. These novel aryl binding pocket moieties represent a structural modification to a series of fXa inhibitors. Several compounds proved to be efficacious i.v. antithrombotic agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0960-894x(99)00466-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Detection and analysis of potential drug-drug interactions among patients admitted to the cardiac care unit in a tertiary care hospital.
Eur Rev Med Pharmacol Sci
January 2023
Department of Clinical Pharmacy, Beni-Suef University Hospital, Beni-Suef University, Egypt.
Objective: This study aimed to estimate how prevalent potential drug-drug interactions (pDDIs) were in patients with cardiovascular diseases who were hospitalized for more than 24 hours, and to determine the risk factors associated with these pDDIs.
Patients And Methods: A prospective observational study was conducted on patients admitted to the cardiac care unit in a tertiary care hospital. We included two hundred medical records of cardiovascular disease patients who were prescribed more than one drug.
Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.
Hum Genomics
September 2022
Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box: 15551, Al-Ain, United Arab Emirates.
Article Synopsis
- Pharmacogenomic (PGx) testing is shown to be effective for tailoring cardiovascular disease (CVD) medication dosages, yet it is not routinely included in the UAE healthcare system despite the diverse population.
- A pilot study with 160 patients analyzed genetic variations related to common CVD drugs, revealing that 46.9% of participants may need alternatives to clopidogrel, and 80% have genetic variants affecting warfarin dosing.
- The study highlights the potential for implementing PGx-guided therapy in the UAE, emphasizing the importance of personalized medication strategies for better healthcare outcomes.
Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction.
PLoS One
September 2022
Complex Fluids Group, Instituto de Física, Universidade de São Paulo, São Paulo, Brazil.
Article Synopsis
- This study investigates how different combinations of antiplatelet and lipid-lowering therapies affect the quality of low-density lipoprotein (LDL) particles in patients who have experienced an acute myocardial infarction.
- Patients were randomized to receive specific treatments and monitored for six months using various scientific techniques to analyze LDL properties.
- Results showed that ticagrelor combined with either simvastatin/ezetimibe or rosuvastatin led to better LDL quality, with enhanced size and lower oxidation in the particles, indicating a potentially improved cardiovascular profile for these treatment combinations.
Development and Validation of Green Chromatographic Approaches for Simultaneous Determination of Aspirin, Rosuvastatin and Clopidogrel in their Tertiary Mixture.
J Chromatogr Sci
December 2023
Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini st, Cairo 11562, Egypt.
Reduction of environmental pollution sources is the main target of green chemistry; it is applied across the life cycle of a chemical product. Scientists try to switch to eco-friendly practices to diminish the negative impact of chemicals and solvents on the environment. Analytical chemistry is one of the main fields that mounted green chemistry approach.
View Article and Find Full Text PDFInfluence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel : Influence of alternate-day dosing of vonoprazan.
Eur J Clin Pharmacol
June 2022
Center for Clinical Research, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Background: Vonoprazan, a potassium-competitive acid blocker, inhibits gastric acid secretion and attenuates the antiplatelet function of clopidogrel more potently than esomeprazole. We investigated whether alternate-day dosing of vonoprazan might avoid this interaction with clopidogrel while providing sufficient gastric acid inhibition.
Methods: Following 24 h of pH monitoring (control regimen), 12 healthy volunteers received three regimens (clopidogrel-only regimen: clopidogrel 75 mg daily [q.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!